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Items for this week’s Epi Update include: 
• Pertussis cases on the rise in Iowa 
• “Get Ahead of Sepsis” resources available 
• FDA approves new drug to treat influenza 
• In the news: Two years after it started, San Diego declares end to 
deadly hepatitis A outbreak 
• In the news: Early numbers show a drop in opioid-related deaths in 
the state 
• Infographic: Antibiotic resistance patient checklist 
• Meeting announcements and training opportunities 
 
Pertussis cases on the rise in Iowa 
A total of 39 pertussis cases have been reported in Iowa over the last two 
months, with more investigations pending. Many of the cases were unvaccinated. 
  
 
 
Patients diagnosed with pertussis should stay home until five full days of 
appropriate antibiotic treatment or until their cough has lasted 21 days. All 
household contacts of pertussis cases are recommended to receive antibiotic 
prophylaxis. Other contacts may require prophylaxis if they meet certain criteria 
for being high-risk for severe pertussis or if they have close contact with 
someone who meets these criteria. As part of routine follow-up, local public 
health agencies work to identify close contacts of pertussis cases. 
 
For full pertussis guidelines, visit 
wiki.idph.iowa.gov/epimanual/Home/CategoryID/100.  
“Get Ahead of Sepsis” resources available 
The CDC has developed an education campaign for healthcare and public health 
partners to use with patients, caregivers, and families.  Each year, more than 1.5 
million people get sepsis in the United States and the most frequently identified 
pathogens include Staphylococcus aureus, Escherichia coli, and Streptococcus. 
 
The CDC advises that it is important to be familiar with your facility’s guidance for 
managing sepsis, start antibiotics and any other appropriate therapies as soon as 
possible, and re-assess your patient frequently, especially to change or stop 
antibiotic therapy as needed and ensure the right type, dose, and duration are 
being used. 
 
To access the educational materials (including factsheets, signs, and brochures), 
visit www.cdc.gov/sepsis/index.html 
 
FDA approves new drug to treat influenza 
The FDA approved a new medication, baloxavir marboxil (Xofluza), for the 
treatment of uncomplicated influenza in patients 12 years and older who have 
been symptomatic for less than 48 hours. This medication acts by inhibiting cap-
dependent endonuclease to inhibit viral replication. It is available in a 40 mg and 
80 mg tablet. The reported frequencies of adverse effects include diarrhea (3%), 
bronchitis (2%), nausea (1%), nasopharyngitis (1%), and headache (1%). Dosing 
is as follows for patients 12 years (and at least 40 kg) and older: 
• 40 kg to < 80 kg: 40 mg by mouth as a single dose 
• > 80 kg: 80 mg by mouth as single dose 
 
For more information visit: https://reference.medscape.com/drug/xofluza-
baloxavir-marboxil-1000275#0  
 
In the news: Two years after it started, San Diego declares end to deadly 
hepatitis A outbreak 
www.sandiegouniontribune.com/news/health/sd-no-hepa-over20181029-
story.html  
 
In the news: Early numbers show a drop in opioid-related deaths in the 
state 
www.radioiowa.com/2018/10/31/early-numbers-show-a-drop-in-opioid-related-
deaths-in-the-state/  
 
Infographic: Antibiotic resistance patient checklist 
 
 
To view in full size, visit www.shea-online.org/images/OPRW/Graphic4.png.  
Meeting announcements and training opportunities 
None 
 
Have a healthy and happy week! 
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